Background: Secondary aesthetic breast surgery is a complex and challenging scenario. It requires the surgeon to identify contributing factors, provide patient education, make a further management plan, and optimize the conditions for a favorable result. Various techniques have been described in literature but the rate of reoperation is still high. The first author has been using a supero-anterior capsular flap with a neopectoral subcapsular pocket and an implant change in these cases. Objectives: To review the patient characteristics, indications, and early results of using part of the existing implant capsule for secondary subpectoral breast augmentations. Methods: All patients who underwent secondary breast augmentation, over a period of 2 years by the first author (P.M.), using the supero-anterior capsular flap technique were included. The technique involves dissection of a new subpectoral pocket and uses the existing implant capsule as an internal brassiere. Results: A total of 36 patients were operated by this technique. Of these, 17 patients had developed a complication while 19 patients wanted a change in size only. At a mean follow up of 10.2 months, there was no bottoming out, double bubble, or capsular contracture. Conclusions: This reliable technique provides stable results as shown by low rate of complications with the existing follow up.
The previous implant may have been a suboptimal choice with respect to its dimensions, volume, or pocket placement while the existing pocket may be scarred, deformed, or malpositioned. The incidence of reoperation is as high as 29.7% at 10 years after primary augmentation. 2 It is higher after revision surgery [2] [3] [4] and with non-textured implants. 5, 6 This higher revision rate is a driving factor to find a good technique that provides a predictable outcome and long lasting results.
The use of acellular dermal matrix (ADM) has gained popularity in aesthetic breast surgery [7] [8] [9] thanks to its supposed advantages in coverage and support of the lower lateral quadrant and decreased risk of CC. However, there are increased risks of seroma and infection [10] [11] [12] which, together with the high cost of these devices, has possibly prevented their widespread use in secondary cases.
We present our technique of secondary subpectoral breast augmentation by reinforcement of the lower pole using a tissue flap designed from the supero-anterior portion of the existing capsule, as an autologous collagen matrix (ACM).
METHODS
Retrospective review of all consecutive patients with submuscular implants undergoing revision breast augmentation by a single surgeon (P.M.) at our institution, between January 2014 and December 2015. The supero-anterior capsule flap technique was used for all patients. Any patient with a subglandular implant was managed only by a site change to the submuscular plane and was not included.
Patient Evaluation and Perioperative Planning
A detailed patient history was collected. Surgical history included the number of operations, choice of implants, and techniques as well as details of postoperative recovery and any complications. All patients were counselled in accordance with the Declaration of Helsinki guidelines and written informed consent was obtained from them preoperatively. Patient was marked in a standing position with careful attention towards existing asymmetries, skin quality and laxity, state of the soft tissue envelope, CC, and implant malposition.
Surgical Technique
All operations were performed under general anesthesia, augmented with local infiltration of a vasoconstrictor-local anesthetic solution (20 mL of 2% lidocaine and 0.8 mL of 1 mg/mL adrenaline in 140 mL of normal saline). A single dose of clindamycin (500 mg) was administered prior to skin incision. All cases were approached through an inframammary fold (IMF) incision (irrespective of the previous approach) for better visualization and electrocautery was used for further dissection. The implant's capsule, once located, was followed to the inferior pole taking care not to breach it. The dissection was continued posteriorly to raise the capsule and the enclosed implant off the chest wall ( Figure 1A) . Implant was then removed through a transverse incision at the lower pole of the capsule (Figure 1B) . This left the posterior leaf of the capsule free (which was removed, Figure 1C ) while the anterior leaf was still attached to the deep surface of the pectoralis major. This anterior leaf was used as an autologous collagen matrix ( Figure 1D ). Figure 2 shows the close-up steps of the raised capsular flap.
The pocket thus created was washed once with saline and then with an antibiotic solution (4 mL of clindamycin 150 mg/m:, in 200 mL normal saline). The primary surgeon changed gloves and the new implant was handled and inserted only by him ("no touch technique"). The flap was pulled down to cover the lower pole of the new implant ( Figure 3A) . The free edge of the flap was sutured to the chest wall with "0" polydioxanone bidirectional barbed suture (Quill, Surgical Specialties Corporation, Wyomissing, PA) ( Figure 3 ) taking care to avoid damaging the implant. A video demonstrating the technique is available as Supplementary Material at www.aestheticsurgeryjournal.com. For mastopexy, the inframammary incision was extended in to an inverted-T pattern.
All wounds were closed in four layers. 12 The first layer sutured thoracic fascia to Scarpa's fascia of the inferior wound edge. The second layer was between Scarpa's fascia of the superior and inferior wound edges while the third layer was at deep dermal level. The first three layers used "0" polydioxanone bidirectional barbed suture. The final layer of epidermal approximation was achieved by 3/0 absorbable monofilament polyglytone suture (Caprosyn, Covidien, Inc., Minneapolis, MN).
RESULTS
A total of 36 patients were operated by the first author (P.M.) with this technique, between January 2014 through December 2015 (as compared to 332 primary breast augmentation procedures performed in the same time interval). Their average age was 38.8 years (range, 19-65 years; median, 39.5 years). This procedure was carried out at a mean 94.7 months (ie, 7 years and 10.7 months) after the augmentation (range, 9-126 months; median, 108 months).
The operation was carried out due to a bilateral indication in 29 patients, left sided problem in 4 and right side problem in 3 patients. Indications for operation are listed in Table 1 . A total of 17 (out of 36) patients were operated due to preexisting complications while 19 patients primarily wanted a change in breast size.
The existing implant characteristics were known in 31 cases. Of these 31, 15 patients had preexisting round implants with a mean volume of 344 cc (range, 200-475 cc) and 16 had preexisting anatomical implants with a mean volume of 312 cc (range, 220-410 cc). In these patients with anatomical implants, 13 had medium height, 2 had full height, and one had a low height implant present. One had low, 4 had medium, 5 had full, and 6 had extra full projection anatomical implants in place at their preoperative consultation. In total, 25 patients expressed a desire to change the existing breast volume, with 21 wishing for a larger volume and 4 patients preferring a smaller volume to the existing one.
The physical characteristics of the new implants are given in Table 2 . Their mean volume was 379 cc (range, 225-525 cc; median, 375 cc). Five patients had an associated mastopexy as well. A total of 29 patients had a mean increase in volume of 138 cc (range, 15-425 cc), 5 patients had a mean reduction of 72 cc in implant volume (range, 30-140 cc), while 2 patient had the same volume implant replaced.
Mean follow up after the surgery was 10.2 months (range, 6-20 months). There was no incidence of implant bottoming out, double bubble formation, CC, seroma, hematoma, or implant rotation. One patient was explanted at her request even though there was no physical complication.
This was in view of ongoing psychological issues that did not come to light before surgery, despite our rigorous preoperative screening procedure.
Supplemental Figure 1 shows the preoperative and postoperative photographs of a 45-year-old patient who underwent revision breast augmentation with this technique. Figure 4 shows a 32-year-old woman who asked for a revision of implant size only and was managed by the supero-anterior capsular flap technique.
DISCUSSION
Secondary breast augmentation is a difficult area for both the patient and the surgeon. As a result of an increasing number of primary breast augmentations and longer follow-up period, the number of secondary aesthetic breast augmentations has increased. Manufacturer's data shows the incidence of reoperation after a primary breast augmentation is approximately 18.1% to 19.4% at 6 years 3,4 and 29.7% at 10 years. 2 The rates of further surgery are higher after secondary augmentation 13 being 24.1% to 35.1% at 6 years, 3, 4 and 47.3% at a10 years. 2 The most common reasons for revision are due to the patient's desire for a change in size or known complications. 14 However, there is a 2-to 3-fold increase in the incidence of CC, patient dissatisfaction, wrinkling, and implant rotation in secondary procedures. 14 The most common implant-related complication is Baker's grade 3 or 4 CC. [3] [4] [5] [6] The reason for CC is likely multifactorial due to subclinical infection, myofibroblast activity, silicone gel bleed, hematoma, microscopic foreign bodies contributing over a period of time. 15 Other common complications include pocket malposition, infection, hematoma, and thinning of tissues causing (or threatening) implant exposure.
There are multiple reasons for the high incidence of complications after a secondary breast augmentation. In secondary procedures, the likely optimum pocket has already been utilized and is now scarred as well. The surrounding breast tissue, due to the mechanical effects (or possibly an unsuitable implant) and age, has stretched out and undergone thinning and atrophy. The patient may have lost faith in the primary surgeon or be overly anxious and concerned, affecting compliance. These events make it challenging to achieve a satisfactory and stable result after revision mammaplasty and contribute to increased risk of complications and patient dissatisfaction. These risks often compound in further reoperations, hence there is an inherent advantage in having a satisfied patient with a stable result as early in their operative history as possible.
Implants have gone through five generations 16, 17 to find the most biocompatible device. The current generation of form stable, highly cohesive gel, dual barrier implants result in very little gel bleed. Moreover, their surface is not smooth but instead has microscopic irregularities ("texturing") built in to it during the manufacturing process. Surface texturing has been shown to decrease the rate of CC by disrupting the tendency of the myofibroblasts to align themselves along a net vector of contraction. The currently available implant surfaces are either macrotextured (Biocellx, Allergan, Inc., Irvine, CA) or microtextured (Siltex, Mentor, Santa Barbara, CA). Macrotextured implants are created by a "lost salt" technique which results in a relatively large (600-800 micron) irregular fractal shaped texture. The microtextured implants are made from an imprinting technique which results in narrower undulations on the surface, approximately 70 to 150 microns in size. 18 The ingrowth of the tissue within these irregular niches helps in tissue adhesion, especially to resist migration or rotation. 15 Some studies 15 suggest that the surface of the macrotextured implants may be better at decreasing the risk of CC (than their counterparts), potentially due to better disruption of myofibroblast activity. Laboratory tests 19 on cell adhesion between the implant types show some difference but are not conclusive. Although the long-term studies show improved rate of CC in textured (vs smooth) implants, there appears to be little clinical difference within the types of textured implants. 14 All of the implants used in this case series were macrotextured. Surgical techniques have evolved to minimize the risk of clinical or even subclinical hematoma. We use infiltration of vasoconstrictor around the implant pocket and in the pectoralis major for control of perioperative bleeding. The associated local anesthetic helps in the immediate pain relief as well. Specifically blocking the medial pectoral nerve prevents isometric pectoralis contraction during recovery from anesthesia and immediately thereafter. We think that minimising pectoralis contraction helps to prevent opening of any small arterioles on its deeper surface that may cause a subclinical hematoma. When it comes to dissecting a neosubmuscular pocket, a well adherent capsule is difficult to dissect, irrespective of which part is approached to remove it. Maxwell and Gabriel 20 described the neosubpectoral pocket anterior to the anterior capsule whereas our technique of dissecting the new pocket in the plane between the posterior capsule and the chest wall is an alternative. The idea is to have a new and "raw" surface adjacent to the implant in order to promote adherence and prevent malposition. We inject a local anesthetic vasoconstrictor solution along the chest wall before dissection of the posterior leaf that helps in hydrodissection as well as in achieving hemostasis. The "no touch technique" and change of gloves before handling each implant prevents introduction of microscopic foreign bodies in the implant cavity, which may initiate an inflammatory response. Subglandular implants are simply addressed by a site change (to submuscular position), while existing submuscular implants need an appropriate neopectoral pocket. We use the term "neopectoral subcapsular" to distinguish our technique from the case when the new plane is dissected between the muscle and the anterior leaf of the capsule as described by Maxwell. Specifically, it is a reference to the plane of dissection and not to the plane of implant placement. The alternative is to perform a total capsulectomy, necessitating more dissection with a higher risk of short term complications and resulting in a larger cavity that requires a larger implant. Placement of a larger implant may adversely affect the tissue−implant dynamics and increase the risk of long term complications.
Thinning of tissues has traditionally been difficult to address. Acellular dermal matrices (ADMs) are bovine or porcine dermal scaffolds that have been treated to remove allogeneic components. The scaffold allows neovascularisation when implanted under the skin and can provide support and pliability. 21, 22 ADMs have been used in reconstructive, 23, 24 as well as primary, aesthetic breast surgery 5 for several years to provide lower lateral quadrant support. More recently, they have gained popularity for addressing breast deformities after augmentation mammaplasty (eg, implant malposition, tissue thinning, and lower pole laxity). [25] [26] [27] Maxwell et al 26 have suggested that ADMs may have a role in reducing the recurrence of CC, possibly by inhibiting the inflammatory changes necessary for inception of peri-implant capsule. However, the risk of seroma, infection [10] [11] [12] [28] [29] [30] and the associated high cost of these devices have tended to limit their widespread use in aesthetic surgery.
Some authors have suggested using part of the existing breast implant capsule as an alternative to ADMs in correcting breast deformities. The periprosthetic capsule is a physiological reaction of the body to the foreign material comprising the implant shell. This tissue is made up of collagen fibers arranged in a dense network with an excellent blood supply, making it physically strong and physiologically biocompatible. 31, 32 To our knowledge, Imran et al 33 first used the term for an inferiorly based capsular flap to correct a contour defect from a lumpectomy. Since then, many authors have reported using part of this capsule as a local flap in revision breast surgery for correction of aesthetic 34, 35 and reconstructive 36,37 defects.
Wessels et al 34 describe a lower pole capsulotomy and raising capsular flaps from both anterior and posterior leaf and resuture them to each other, in order to elevate the IMF in aesthetic revision surgery. Persichetti et al 35 described their experience in 30 patients (4 aesthetic and 26 reconstruction) of using the inferior part of the capsule as a "sling shot" to raise the IMF. They perform an inferior pole capsulotomy and suture the free end of the capsule higher up with the posterior leaf (but do not excise the posterior leaf). We have used our technique in aesthetic patients only, to create a neopectoral pocket, do a partial capsulectomy (of the posterior leaf of the existing capsule), and anchor the capsular flap to chest wall in order to hold the new implant in place and reduce its weight on the lower pole of the breast.
We have expanded the indication for this procedure to include all cases of secondary subpectoral mammoplasty, whether it is for correction of a known complication or as a form of prevention (in revision surgery without a malposition). We think that physical load of the implant stretches out and deforms the tissue over the long term, contributing towards atrophy of the lower pole of the breast, bottoming out, and descent of the inframammary fold. This stress compromises the local tissue quality even if its physical thickness does not change (eg, in younger patients). Simply replacing an implant without addressing these local factors will almost certainly replace the stress on the local tissues that have already been damaged. Our aim is to reduce the potential for these complications by reinforcing the lower pole using the autologous collagen matrix of the existing capsule as an internal brassiere. This, in turn, would help achieve stable and long lasting results.
There may be concern about the ability of the capsule to hold an implant. However, considering the fact that subfascial breast implantation is a well-described technique that utilizes the prepectoral fascia, if an implant can be held in position by a flimsy looking prepectoral fascia, it can potentially be supported by the capsule as well. There is biomechanical evidence to suggest that the mechanical strength of an implant capsule is comparable to that of skin. The upper limit of mean tensile strength of Baker grade 1 capsule is 2.8 MPa which increases to 8.8 MPa for Baker grade 3 and 11.5 MPa for Baker grade 4 contracture. 38 In comparison, porcine or bovine ADMs have a mean tensile strength of 11.8 to 18.5 MPa 39 whereas skin has a mean ultimate tensile strength of 21.6 MPa. There is no current biomechanical model that predicts the minimum strength needed to support an implant of a given weight. Empirically however, if an implant can be supported by a flimsy looking thoracic fascia, a capsule can offer it equivalent (if not better) mechanical support. Clinically, we have noticed that thin capsules appear to have enough strength to hold an implant. In fact, thinner capsules may be a better indication for this technique due to lesser chance of an associated biofilm.
Maxwell's technique 20 is the nearest comparison to ours but their primary indication was CC (in 67.9% of cases) and they used ADMs in 28% of patients, which have been shown to independently decrease the rate of CC. In our series, only 7 patients (out of 36, 16.7%) patients were operated due to existing CC and we did not use any ADM.
The presence of CC in a patient raises the possibility of a biofilm. In their technique, Maxwell and Gabriel, 20 leave the whole capsule intact but wash the cavity with antibiotics. As the biofilm is present throughout the capsule, this amounts to leaving the biofilm in situ. However, they do wash the cavity with antibiotics (and we do the same too). We remove the posterior leaf of the capsule and wash the resulting cavity thoroughly with saline and instill clindamicin solution in it before replacing the new implant. Current evidence 42 suggests that the Staphylococcus species is significantly associated with the implant capsules, and Staph is sensitive to clindamicin. It must also be noticed that not all capsules are associated with biofilm. 43 The reason to perform this technique is 2-fold. Firstly, to have the implant lie on a "new" raw surface, even in cases that present with no complication (ie, size change). This raw surface is necessary to promote adhesion of the new anatomical implant and a prerequisite to avoiding malposition. Secondly, most of the patients undergoing such surgery want a larger (ie, heavier) implant. Using a capsular flap helps take some of the load off the tissues in the lower pole. The capsular flap, thus acts like an internal brasserie that holds the implant in place reducing its weight on the lower pole of the breast. The main risks of capsulectomy include difficult dissection during the operation or postoperative hematoma. While ease of dissection may be a subjective statement, we did not have any postoperative hematoma either. The absence of any postoperative complication in this series shows that, at least in our hands, the risks (of a posterior capsulectomy) do not outweigh the benefits. This technique is for implant placement in secondary aesthetic augmentation. If used in established CC there may be risk of recurrence, due to the presence of a bacterial biofilm. This recurrence risk after partial capsulectomy for secondary aesthetic breast augmentation is not well documented in the literature. 40 Collis and Sharpe 41 compared outcomes after anterior or total capsulectomy in 103 patients (172 breasts) who had 87 primary CC and 16 recurrent CC after subglandular implantation with (predominantly) smooth silicone implants. They irrigated the cavity with povidone-iodine and did not perform an implant site change. Seventy-nine breasts had anterior capsulectomy while 93 had total capsulectomy. They found recurrence in 50% breasts at mean 6.9 years after partial capsulectomy and 10% breasts at mean 3.1 years follow up after total capsulectomy. In our series, only 7 out of 36 patients had a capsule contracture. The surgery was carried out by the first author with atraumatic technique and sharp dissection while ensuring a blood less field. The implant and its pocket were irrigated with antibiotic efficacious against Staphylococcal species. The implants were handled with a "no-touch technique" to counteract any existing biofilm in the remaining capsule and minimise introduction of a subclinical infection they may contribute to the risk of CC recurrence. The suitability of our technique for CC can only be judged with a longer clinical follow up. We note that there is no research on the concentration or the duration of contact of any antibiotic with the existing capsule that is effective in removal of the associated biofilm. We do not recommend this technique in cases with chronic low grade infection (or in case of gel rupture).
Our mean follow up was 10.2 months and demonstrated a stable result with the use of this capsular flap technique with neither postoperative infections nor implant malposition or bottoming out. Admittedly, this follow up is not long enough to definitively comment on capsule formation as only approximately 10% of these complications will be apparent at this stage. 3 However, we did not have any postoperative complications (eg, hematoma) from the posterior capsulectomy. In our experience this is a simple and effective technique that can actually improve the outcome and help achieve good results in revision augmentation mammoplasty, without incurring the additional cost of ADM. We reserve the use of ADMs only to selected patients (bottoming out of heavy implants, severe tissue thinning out, recurrent CC), who accept to bear the cost and the risks of these devices.
CONCLUSION
Neopectoral subcapsular pocket has not previously been described for secondary aesthetic breast augmentation. In an effort to improve the outcome and durability of result after aesthetic breast revision surgery, we utilize a capsular flap raised from the antero-superior surface of the peripros-thetic capsule. It is used to support the implant and to reinforce the weakened breast tissue. We use this technique to correct or prevent implant malposition. The posterior capsulectomy is to provide a raw surface for implant adherence and the capsular flap shares some of the mechanical load of the implant. We have also used this technique in a small number of cases with established CC while taking strict intraoperative precautions to minimize risk from any established biofilm. In our patient series we had reliable and stable aesthetic outcome and this technique has become the procedure of choice of the first author, for all subpectoral breast revision surgery that include implant change. A longer follow up will help in understanding the long term stability of the result and any complications.
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